Novartis AG (SWX:NOVN)
| Market Cap | 242.46B +19.5% |
| Revenue (ttm) | 47.86B +1.8% |
| Net Income | 8.37B -30.3% |
| EPS | 4.37 -28.3% |
| Shares Out | 1.89B |
| PE Ratio | 29.41 |
| Forward PE | 15.95 |
| Dividend | 3.70 (2.88%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 760,868 |
| Open | 128.44 |
| Previous Close | 131.48 |
| Day's Range | 127.88 - 129.68 |
| 52-Week Range | 99.45 - 137.00 |
| Beta | 0.45 |
| Analysts | Hold |
| Price Target | 129.70 (+1.03%) |
| Earnings Date | Oct 27, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia ... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for NOVN stock is "Hold." The 12-month stock price target is CHF 129.70, which is an increase of 1.03% from the latest price.
News
Novartis AG Press release: FY 2026
Novartis AG issued a press release on November 19, 2026, disclosing material business information to investors.
Novartis AG Slides: FY 2026
Novartis AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 19, 2026.
Novartis AG Press release: FY 2026
Novartis AG issued a press release on November 19, 2026, disclosing material business information to investors.
Novartis AG Slides: FY 2026
Novartis AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 19, 2026.
Novartis bets on bigger blockbusters to power growth, forecasting 5% annual sales through 2031
Ahead of its Capital Markets Day on Thursday, Novartis upgraded its peak sales outlook for three of its blockbuster drugs to a combined $18 billion, up from a previous forecast of a combined $14 billi...
Novartis AG Transcript: Meet Novartis Management 2026 Part 1
Sales growth guidance is 5% for 2026-2031, with mid-single-digit average growth targeted through 2035 and a 40% core margin by 2029. Management highlighted an expanding late-stage pipeline, AI-driven productivity and U.S. manufacturing expansion.
Novartis AG Press release: FY 2026
Novartis AG issued a press release on November 19, 2026, disclosing material business information to investors.
Novartis AG Slides: FY 2026
Novartis AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 19, 2026.
Novartis Projects 5% Annual Sales Growth In CC Through 2031, Sustained Growth Over Long Term
(RTTNews) - Swiss drug major Novartis AG (NVS, NOVN.SW) Thursday announced its mid-term guidance to 2026-2031, with net sales expected to grow 5 percent at constant currency CAGR. The firm added that ...
Novartis Sees Sales Growth Through 2031
The drugmaker expects annual sales growth of 5% from 2026 to 2031, from a previous forecast of 5% to 6% over the 2025-30 period.
Novartis targets 5% annual sales growth through 2031
Swiss drugmaker Novartis on Thursday outlined new mid-term sales targets that were at the lower end of the range it had given a year earlier, ahead of its annual investor event in London.
Novartis reports FDA approves Cosentyx for polymyalgia rheumatica
Novartis (NVS) announced that the U.S. Food and Drug Administration approved Cosentyx 150 mg for the treatment of adult patients with polymyalgia rheumatica who have had an inadequate response to…
Novartis' Cosentyx Wins FDA Approval As First Anti-IL-17 Biologic For Polymyalgia Rheumatica
(RTTNews) - On Tuesday, Novartis AG (NVS) said the U.S. FDA approved Cosentyx 150 mg for adults with polymyalgia rheumatica who have responded inadequately to corticosteroids or cannot tolerate steroi...
Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)
Basel, November 17, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) approved Cosentyx® (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumati...
Novartis Wins Positive CHMP Opinion For Cosentyx In Adolescent Hidradenitis Suppurativa
(RTTNews) - Novartis (NVS, NOVN.SW) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx (secukinumab) for adol...
Novartis reports positive CHMP opinion for Cosentyx in adolescents 12 and older
Novartis (NVS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization of Cosentyx for ad...
Novartis says long-term Rhapsido data show sustained efficacy
Novartis (NVS) announced 52-week results from the Phase III RemIND program evaluating Rhapsido in chronic inducible urticaria. In the long-term analysis from the RemIND study, Rhapsido 25 mg twice dai...
Novartis' Ianalumab Shows Continued Benefits In Two-Year Sjögren's Study
(RTTNews) - Novartis AG (NVS, NOVN.SW) on Tuesday reported encouraging two-year results from its ongoing Phase 3 NEPTUNUS extension study of investigational drug ianalumab, showing further improvement...
Novartis presents long-term results from ongoing NEPTUNUS extension study
Novartis (NVS) presented long-term results from the ongoing NEPTUNUS extension study of ianalumab in Sjogren’s disease at the American College of Rheumatology Convergence 2026. The data showed that th...
How IBD Stock Of The Day TG Therapeutics Is Catching Up To Roche, Novartis
TG Therapeutics is Tuesday's IBD Stock Of The Day. Shares topped a buy zone despite a mixed Q3 report, but are in range of an alternate entry.
Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer
LLY, NVS and BAYRY stand out as the pharma sector rebounds in 2026, supported by innovative drug pipelines, strong product demand and rising earnings estimates.
A failed trial for a heart drug casts shadow over rivals developing similar therapies
The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels.
Novartis drops heart drug after it failed to prevent heart attacks
Novartis is ending development of pelacarsen in heart disease. In a study of more than 8,300 patients the drug cut Lp(a) levels by 78% but did not reduce heart attacks or strokes.
Novartis to discontinue development of pelacarsen, Bloomberg says
Novartis (NVS) is discontinuing the development of pelacarsen, a drug that was meant to treat atherosclerotic cardiovascular disease, Fabienne Kinzelmann and Robert Langreth of Bloomberg reports. The ...
Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing
An experimental Novartis drug designed to treat a genetic cause of heart disease failed to reduce deaths and non-fatal heart attacks, dashing hopes for the first of several such drugs in clinical tria...